Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo

Zeng B. Zhu, Sharmila K. Makhija, Baogen Lu, Minghui Wang, Angel A. Rivera, Sangae Kim-Park, Ilya V. Ulasov, Fen Zhou, Ronald D. Alvarez, Gene P. Siegal, David T. Curiel

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Conditionally replicating adenoviruses (CRAds) represent a promising new modality for the treatment of cancer. A key contribution in this regard was the introduction of tumor-selective viral replication for amplification of the initial inoculum. Specifically, following cellular infection, the virus replicates selectively in the infected tumor cells and kills the cells by cytolysis. Next, the progeny virions infect surrounding target cells, replicate and eradicate the infected tumor cells, leaving normal cells unaffected. However, to date there have been two limitations to clinical application of these CRAd agents; i.e., both infectivity and tumor specificity are poor. Survivin protein is a novel member of the inhibitor of apoptosis (IAP) protein family, which plays an important role in the survival of cancer cells and progression of malignancies. Previous data have shown the survivin promoter has high activities in multiple cancer cells with a low activity in mouse liver. In this study, we propose an improved CRAd agent to circumvent the obstacles. We constructed a novel CRAd agent, CRAd-Survivin-RGD, which contains both the survivin promoter (either the short version, S-S, or the long version, S-L) to selectively drive El gene expression in tumor cells and a capsid modification and RGD4C to specifically enhance the tumor infectivity of CRAd agents. Both CRAd agents (S-S and S-L) showed high replication rates in the breast cancer cell line, MDA-MB-361, and low promoter activity in both normal mouse and human liver, thus signifying the CRAd agents have the phenotype of 'tumor on/liver off. In cytocidal experiments, the CRAd agents demonstrated a high cytocidal effect on multiple cancer cell lines, including the breast cancer cell line, MDA-MB-231; the glioma cell line, D65, the melanoma cell line, MEL-28; and mesothelioma, Meso2374. The results also showed the tumor growth was dramatically inhibited by intertumoral administration of the CRAd agents in a breast cancer (MDA-MB-361) xenograft animal model. These data clearly demonstrate that CRAd- Survivin-RGD is a potential novel therapeutic agent for treatment in many, but not all, human cancers.

Original languageEnglish (US)
Pages (from-to)237-246
Number of pages10
JournalInternational Journal of Oncology
Volume27
Issue number1
StatePublished - Jul 2005
Externally publishedYes

Fingerprint

Adenoviridae
Neoplasms
Cell Line
Breast Neoplasms
In Vitro Techniques
Liver
Inhibitor of Apoptosis Proteins
Capsid
Mesothelioma
Virus Diseases
Heterografts
Glioma
Virion
Melanoma
Cell Survival
Animal Models

Keywords

  • Adenoviral vector
  • Survivin gene
  • Transcriptional targeting
  • Tumor-specific promoter

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo. / Zhu, Zeng B.; Makhija, Sharmila K.; Lu, Baogen; Wang, Minghui; Rivera, Angel A.; Kim-Park, Sangae; Ulasov, Ilya V.; Zhou, Fen; Alvarez, Ronald D.; Siegal, Gene P.; Curiel, David T.

In: International Journal of Oncology, Vol. 27, No. 1, 07.2005, p. 237-246.

Research output: Contribution to journalArticle

Zhu, ZB, Makhija, SK, Lu, B, Wang, M, Rivera, AA, Kim-Park, S, Ulasov, IV, Zhou, F, Alvarez, RD, Siegal, GP & Curiel, DT 2005, 'Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo', International Journal of Oncology, vol. 27, no. 1, pp. 237-246.
Zhu, Zeng B. ; Makhija, Sharmila K. ; Lu, Baogen ; Wang, Minghui ; Rivera, Angel A. ; Kim-Park, Sangae ; Ulasov, Ilya V. ; Zhou, Fen ; Alvarez, Ronald D. ; Siegal, Gene P. ; Curiel, David T. / Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo. In: International Journal of Oncology. 2005 ; Vol. 27, No. 1. pp. 237-246.
@article{5ba1764fb9a641a99a686a58d2842562,
title = "Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo",
abstract = "Conditionally replicating adenoviruses (CRAds) represent a promising new modality for the treatment of cancer. A key contribution in this regard was the introduction of tumor-selective viral replication for amplification of the initial inoculum. Specifically, following cellular infection, the virus replicates selectively in the infected tumor cells and kills the cells by cytolysis. Next, the progeny virions infect surrounding target cells, replicate and eradicate the infected tumor cells, leaving normal cells unaffected. However, to date there have been two limitations to clinical application of these CRAd agents; i.e., both infectivity and tumor specificity are poor. Survivin protein is a novel member of the inhibitor of apoptosis (IAP) protein family, which plays an important role in the survival of cancer cells and progression of malignancies. Previous data have shown the survivin promoter has high activities in multiple cancer cells with a low activity in mouse liver. In this study, we propose an improved CRAd agent to circumvent the obstacles. We constructed a novel CRAd agent, CRAd-Survivin-RGD, which contains both the survivin promoter (either the short version, S-S, or the long version, S-L) to selectively drive El gene expression in tumor cells and a capsid modification and RGD4C to specifically enhance the tumor infectivity of CRAd agents. Both CRAd agents (S-S and S-L) showed high replication rates in the breast cancer cell line, MDA-MB-361, and low promoter activity in both normal mouse and human liver, thus signifying the CRAd agents have the phenotype of 'tumor on/liver off. In cytocidal experiments, the CRAd agents demonstrated a high cytocidal effect on multiple cancer cell lines, including the breast cancer cell line, MDA-MB-231; the glioma cell line, D65, the melanoma cell line, MEL-28; and mesothelioma, Meso2374. The results also showed the tumor growth was dramatically inhibited by intertumoral administration of the CRAd agents in a breast cancer (MDA-MB-361) xenograft animal model. These data clearly demonstrate that CRAd- Survivin-RGD is a potential novel therapeutic agent for treatment in many, but not all, human cancers.",
keywords = "Adenoviral vector, Survivin gene, Transcriptional targeting, Tumor-specific promoter",
author = "Zhu, {Zeng B.} and Makhija, {Sharmila K.} and Baogen Lu and Minghui Wang and Rivera, {Angel A.} and Sangae Kim-Park and Ulasov, {Ilya V.} and Fen Zhou and Alvarez, {Ronald D.} and Siegal, {Gene P.} and Curiel, {David T.}",
year = "2005",
month = "7",
language = "English (US)",
volume = "27",
pages = "237--246",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo

AU - Zhu, Zeng B.

AU - Makhija, Sharmila K.

AU - Lu, Baogen

AU - Wang, Minghui

AU - Rivera, Angel A.

AU - Kim-Park, Sangae

AU - Ulasov, Ilya V.

AU - Zhou, Fen

AU - Alvarez, Ronald D.

AU - Siegal, Gene P.

AU - Curiel, David T.

PY - 2005/7

Y1 - 2005/7

N2 - Conditionally replicating adenoviruses (CRAds) represent a promising new modality for the treatment of cancer. A key contribution in this regard was the introduction of tumor-selective viral replication for amplification of the initial inoculum. Specifically, following cellular infection, the virus replicates selectively in the infected tumor cells and kills the cells by cytolysis. Next, the progeny virions infect surrounding target cells, replicate and eradicate the infected tumor cells, leaving normal cells unaffected. However, to date there have been two limitations to clinical application of these CRAd agents; i.e., both infectivity and tumor specificity are poor. Survivin protein is a novel member of the inhibitor of apoptosis (IAP) protein family, which plays an important role in the survival of cancer cells and progression of malignancies. Previous data have shown the survivin promoter has high activities in multiple cancer cells with a low activity in mouse liver. In this study, we propose an improved CRAd agent to circumvent the obstacles. We constructed a novel CRAd agent, CRAd-Survivin-RGD, which contains both the survivin promoter (either the short version, S-S, or the long version, S-L) to selectively drive El gene expression in tumor cells and a capsid modification and RGD4C to specifically enhance the tumor infectivity of CRAd agents. Both CRAd agents (S-S and S-L) showed high replication rates in the breast cancer cell line, MDA-MB-361, and low promoter activity in both normal mouse and human liver, thus signifying the CRAd agents have the phenotype of 'tumor on/liver off. In cytocidal experiments, the CRAd agents demonstrated a high cytocidal effect on multiple cancer cell lines, including the breast cancer cell line, MDA-MB-231; the glioma cell line, D65, the melanoma cell line, MEL-28; and mesothelioma, Meso2374. The results also showed the tumor growth was dramatically inhibited by intertumoral administration of the CRAd agents in a breast cancer (MDA-MB-361) xenograft animal model. These data clearly demonstrate that CRAd- Survivin-RGD is a potential novel therapeutic agent for treatment in many, but not all, human cancers.

AB - Conditionally replicating adenoviruses (CRAds) represent a promising new modality for the treatment of cancer. A key contribution in this regard was the introduction of tumor-selective viral replication for amplification of the initial inoculum. Specifically, following cellular infection, the virus replicates selectively in the infected tumor cells and kills the cells by cytolysis. Next, the progeny virions infect surrounding target cells, replicate and eradicate the infected tumor cells, leaving normal cells unaffected. However, to date there have been two limitations to clinical application of these CRAd agents; i.e., both infectivity and tumor specificity are poor. Survivin protein is a novel member of the inhibitor of apoptosis (IAP) protein family, which plays an important role in the survival of cancer cells and progression of malignancies. Previous data have shown the survivin promoter has high activities in multiple cancer cells with a low activity in mouse liver. In this study, we propose an improved CRAd agent to circumvent the obstacles. We constructed a novel CRAd agent, CRAd-Survivin-RGD, which contains both the survivin promoter (either the short version, S-S, or the long version, S-L) to selectively drive El gene expression in tumor cells and a capsid modification and RGD4C to specifically enhance the tumor infectivity of CRAd agents. Both CRAd agents (S-S and S-L) showed high replication rates in the breast cancer cell line, MDA-MB-361, and low promoter activity in both normal mouse and human liver, thus signifying the CRAd agents have the phenotype of 'tumor on/liver off. In cytocidal experiments, the CRAd agents demonstrated a high cytocidal effect on multiple cancer cell lines, including the breast cancer cell line, MDA-MB-231; the glioma cell line, D65, the melanoma cell line, MEL-28; and mesothelioma, Meso2374. The results also showed the tumor growth was dramatically inhibited by intertumoral administration of the CRAd agents in a breast cancer (MDA-MB-361) xenograft animal model. These data clearly demonstrate that CRAd- Survivin-RGD is a potential novel therapeutic agent for treatment in many, but not all, human cancers.

KW - Adenoviral vector

KW - Survivin gene

KW - Transcriptional targeting

KW - Tumor-specific promoter

UR - http://www.scopus.com/inward/record.url?scp=24644441665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24644441665&partnerID=8YFLogxK

M3 - Article

C2 - 15942665

AN - SCOPUS:24644441665

VL - 27

SP - 237

EP - 246

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 1

ER -